title: Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells.
abstract: Human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC) have been the standards for cell-based assays in the field of angiogenesis research and in antiangiogenic drug discovery. These normal mature endothelial cells may not be most representative of human tumor endothelial cells. Human AC133+/CD34+ bone marrow progenitor cells were established in cell culture media containing vascular endothelial growth factor, basic fibroblast growth factor (bFGF), and heparin to drive differentiation toward the endothelial phenotype. The resulting cells designated endothelial precursor cells (EPC) have many of the same functional properties as mature endothelial cells represented by HUVEC and HMVEC. By SAGE analysis, the genes expressed by EPC are more similar to the genes expressed by endothelial cells isolated from fresh surgical specimens of human tumors than are the genes expressed by HUVEC and HMVEC. Analysis of several cell surface markers by flow cytometry showed that EPC, HUVEC, and HMVEC have similar expression of P1H12, vascular endothelial growth factor 2, and endoglin but that EPC have much lower expression of ICAM1, ICAM2, VCAM1, and thrombomodulin than do HUVEC and HMVEC. The EPC generated can form tubes/networks on Matrigel, migrate through porous membranes, and invade through thin layers of Matrigel similarly to HUVEC and HMVEC. However, in a coculture assay using human SKOV3 ovarian cancer cell clusters in collagen as a stimulus for invasion through Matrigel, EPC were able to invade into the malignant cell cluster, whereas HMVEC were not able to invade the malignant cell cluster. In vivo, a Matrigel plug assay where human EPC were suspended in the Matrigel allowed tube/network formation by human EPC to be carried out in a murine host. EPC may be a better model of human tumor endothelial cells than HUVEC and HMVEC and, thus, may provide an improved cell-based model for second generation antineoplastic antiangiogenic drug discovery.
authors.affiliation: Genzyme Corp., Framingham, Massachusetts 01701-9322, USA.
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Bagley
authors.forename: Jennifer
authors.initials: J
authors.lastname: Walter-Yohrling
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Cao
authors.forename: William
authors.initials: W
authors.lastname: Weber
authors.forename: Betsy
authors.initials: B
authors.lastname: Simons
authors.forename: Brian P
authors.initials: BP
authors.lastname: Cook
authors.forename: Scott D
authors.initials: SD
authors.lastname: Chartrand
authors.forename: Clarence
authors.initials: C
authors.lastname: Wang
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Madden
authors.forename: Beverly A
authors.initials: BA
authors.lastname: Teicher
mesh_terms: D018952:Antigens, CD34 / Q000096:biosynthesis; D001854:Bone Marrow Cells / Q000166:cytology / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology*; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000096:biosynthesis
chemical_list: D018952:Antigens, CD34; D040301:Vascular Endothelial Growth Factor Receptor-2